Abstract
Background: The incidence of acute coronary syndrome is reported to be higher for males than females, yet clinical outcomes following acute myocardial infarction are worse among females. Information about acute coronary syndrome outcomes is obtained from randomised and cohort data. However, randomised controlled trials which are designed to evaluate the efficacy of clinical interventions often have limited external validity, and observational studies which draw inferences from the effect of an exposure whilst being more generalizable are limited by confounding. Methods: We undertook a structured literature review of research manuscripts published between 2000 and 2015 to examine whether reported sex-dependent outcomes following acute coronary syndrome differed between randomised control trials and observational registries. Results: Of 56 manuscripts, we found consistency between the two types of study designs – each type of study describing worse clinical outcomes for females with acute coronary syndrome. We also found a reduction in the use of guideline recommended therapy in females. Conclusion: Further research is needed to understand at a mechanistic and health services level why such a discrepancy in clinical outcomes exists.
Keywords: Acute coronary syndrome, sex outcomes, trials, registries.
Current Pharmaceutical Design
Title:Are Sex Differences in Outcomes of Patients with ACS from Observational Registries Similar to the Findings from Randomized Clinical Trials?
Volume: 22 Issue: 25
Author(s): Chris P. Gale and Owen Bebb
Affiliation:
Keywords: Acute coronary syndrome, sex outcomes, trials, registries.
Abstract: Background: The incidence of acute coronary syndrome is reported to be higher for males than females, yet clinical outcomes following acute myocardial infarction are worse among females. Information about acute coronary syndrome outcomes is obtained from randomised and cohort data. However, randomised controlled trials which are designed to evaluate the efficacy of clinical interventions often have limited external validity, and observational studies which draw inferences from the effect of an exposure whilst being more generalizable are limited by confounding. Methods: We undertook a structured literature review of research manuscripts published between 2000 and 2015 to examine whether reported sex-dependent outcomes following acute coronary syndrome differed between randomised control trials and observational registries. Results: Of 56 manuscripts, we found consistency between the two types of study designs – each type of study describing worse clinical outcomes for females with acute coronary syndrome. We also found a reduction in the use of guideline recommended therapy in females. Conclusion: Further research is needed to understand at a mechanistic and health services level why such a discrepancy in clinical outcomes exists.
Export Options
About this article
Cite this article as:
P. Gale Chris and Bebb Owen, Are Sex Differences in Outcomes of Patients with ACS from Observational Registries Similar to the Findings from Randomized Clinical Trials?, Current Pharmaceutical Design 2016; 22 (25) . https://dx.doi.org/10.2174/1381612822666160426150626
DOI https://dx.doi.org/10.2174/1381612822666160426150626 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Classes of Dimer Antitumour Drug Candidates
Current Pharmaceutical Design Pulmonary Hypertension: Role of Combination Therapy
Current Vascular Pharmacology The Pathophysiology of Heart Failure in Children: The Basics
Current Cardiology Reviews Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence
Current Pharmaceutical Design Targeting Calcium and the Mitochondria in Prevention of Pathology in the Heart
Current Drug Targets Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Current Medicinal Chemistry Gene Delivery System: A Developing Arena of Study for the New Era of Medicine
Recent Patents on DNA & Gene Sequences Synthesis and Bioactivities of 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors
Medicinal Chemistry Erythropoiesis Stimulating Agents and Anaemia of End-Stage Renal Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Hypoxia-Inducible Factors and Sphingosine 1-Phosphate Signaling
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Endothelial Dysfunction: Clinical Significance and Preventive Non-Pharmacological Therapeutic Strategies
Current Pharmaceutical Design Crocetin: an Agent Derived from Saffron for Prevention and Therapy for Cancer
Current Pharmaceutical Biotechnology Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review
Current Cardiology Reviews The “Aged Garlic Extract” (AGE) and One of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer's Disease (AD)
Current Medicinal Chemistry Thrombolysis in Ischemic Stroke: Focus on New Treatment Strategies
Recent Patents on Cardiovascular Drug Discovery Forkhead Genes: Their Role and Impact on Ocular Developmental Diseases
Current Genomics Traditional and Alternative Therapies for Refractory Angina
Current Pharmaceutical Design Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Cardiovascular & Hematological Agents in Medicinal Chemistry An Update to Enterococcal Bacteremia: Epidemiology, Resistance, and Outcome
Infectious Disorders - Drug Targets